Innova Vascular, Inc. (Innova) has submitted a 510(k) Premarket Notification to the U.S. Food and Drug Administration (FDA) for its thrombectomy devices intended to treat peripheral vascular disease, according to Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company that develops and commercialises innovative interventional treatment systems for patients with peripheral and coronary artery disease.
To remove blood clots from veins and arteries, doctors perform thrombectomy, an interventional procedure that is rapidly gaining popularity. Each of the cutting-edge thrombectomy devices from Innova that target peripheral vascular disease will be purchased and made available for sale by CSI. The thrombectomy devices' commercialization will be a great addition to CSI's larger portfolio of cutting-edge technologies for the treatment of Cardiovascular Information System.
Read More:
